1
|
Ostermann AL, Wunderlich CM, Schneiders L, Vogt MC, Woeste MA, Belgardt BF, Niessen CM, Martiny B, Schauss AC, Frommolt P, Nikolaev A, Hövelmeyer N, Sears RC, Koch PJ, Günzel D, Brüning JC, Wunderlich FT. Intestinal insulin/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer. Nat Metab 2019; 1:371-389. [PMID: 32694718 DOI: 10.1038/s42255-019-0037-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 01/24/2019] [Indexed: 12/30/2022]
Abstract
Obesity promotes the development of insulin resistance and increases the incidence of colitis-associated cancer (CAC), but whether a blunted insulin action specifically in intestinal epithelial cells (IECs) affects CAC is unknown. Here, we show that obesity impairs insulin sensitivity in IECs and that mice with IEC-specific inactivation of the insulin and IGF1 receptors exhibit enhanced CAC development as a consequence of impaired restoration of gut barrier function. Blunted insulin signalling retains the transcription factor FOXO1 in the nucleus to inhibit expression of Dsc3, thereby impairing desmosome formation and epithelial integrity. Both IEC-specific nuclear FoxO1ADA expression and IEC-specific Dsc3 inactivation recapitulate the impaired intestinal integrity and increased CAC burden. Spontaneous colonic tumour formation and compromised intestinal integrity are also observed upon IEC-specific coexpression of FoxO1ADA and a stable Myc variant, thus suggesting a molecular mechanism through which impaired insulin action and nuclear FOXO1 in IECs promotes CAC.
Collapse
Affiliation(s)
- A L Ostermann
- Max Planck Institute for Metabolism Research, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany
| | - C M Wunderlich
- Max Planck Institute for Metabolism Research, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - L Schneiders
- Max Planck Institute for Metabolism Research, Cologne, Germany
| | - M C Vogt
- Max Planck Institute for Metabolism Research, Cologne, Germany
| | - M A Woeste
- Max Planck Institute for Metabolism Research, Cologne, Germany
| | - B F Belgardt
- Max Planck Institute for Metabolism Research, Cologne, Germany
- German Diabetes Center (DDZ), Düsseldorf, Germany
| | - C M Niessen
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - B Martiny
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
| | - A C Schauss
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
| | - P Frommolt
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
| | - A Nikolaev
- Institute for Molecular Medicine, University Hospital Mainz, Mainz, Germany
| | - N Hövelmeyer
- Institute for Molecular Medicine, University Hospital Mainz, Mainz, Germany
| | - R C Sears
- Department of Molecular and Medical Genetics, Oregon Health & Sciences University, Portland, OR, USA
| | - P J Koch
- Department of Dermatology, Charles C. Gates Regenerative Medicine and Stem Cell Biology Program, University of Colorado Denver, Aurora, CO, USA
| | - D Günzel
- Institute for Clinical Physiology, Charité, Berlin, Germany
| | - J C Brüning
- Max Planck Institute for Metabolism Research, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - F T Wunderlich
- Max Planck Institute for Metabolism Research, Cologne, Germany.
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
- Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany.
| |
Collapse
|
2
|
Woeste MA, Stern S, Raju DN, Grahn E, Dittmann D, Gutbrod K, Dörmann P, Hansen JN, Schonauer S, Marx CE, Hamzeh H, Körschen HG, Aerts JMFG, Bönigk W, Endepols H, Sandhoff R, Geyer M, Berger TK, Bradke F, Wachten D. Species-specific differences in nonlysosomal glucosylceramidase GBA2 function underlie locomotor dysfunction arising from loss-of-function mutations. J Biol Chem 2019; 294:3853-3871. [PMID: 30662006 DOI: 10.1074/jbc.ra118.006311] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 01/16/2019] [Indexed: 11/06/2022] Open
Abstract
The nonlysosomal glucosylceramidase β2 (GBA2) catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP), autosomal-recessive cerebellar ataxia (ARCA), and the Marinesco-Sjögren-like syndrome. However, the underlying molecular mechanisms are ill-defined. Here, using biochemistry, immunohistochemistry, structural modeling, and mouse genetics, we demonstrate that all but one of the spastic gait locus #46 (SPG46)-connected mutations cause a loss of GBA2 activity. We demonstrate that GBA2 proteins form oligomeric complexes and that protein-protein interactions are perturbed by some of these mutations. To study the pathogenesis of GBA2-related HSP and ARCA in vivo, we investigated GBA2-KO mice as a mammalian model system. However, these mice exhibited a high phenotypic variance and did not fully resemble the human phenotype, suggesting that mouse and human GBA2 differ in function. Whereas some GBA2-KO mice displayed a strong locomotor defect, others displayed only mild alterations of the gait pattern and no signs of cerebellar defects. On a cellular level, inhibition of GBA2 activity in isolated cerebellar neurons dramatically affected F-actin dynamics and reduced neurite outgrowth, which has been associated with the development of neurological disorders. Our results shed light on the molecular mechanism underlying the pathogenesis of GBA2-related HSP and ARCA and reveal species-specific differences in GBA2 function in vivo.
Collapse
Affiliation(s)
- Marina A Woeste
- From the Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany
| | - Sina Stern
- the German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany
| | - Diana N Raju
- From the Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany
| | - Elena Grahn
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Dominik Dittmann
- From the Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany
| | - Katharina Gutbrod
- the Institute of Molecular Physiology and Biotechnology of Plants, University of Bonn, 53115 Bonn, Germany
| | - Peter Dörmann
- the Institute of Molecular Physiology and Biotechnology of Plants, University of Bonn, 53115 Bonn, Germany
| | - Jan N Hansen
- From the Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany
| | - Sophie Schonauer
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Carina E Marx
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Hussein Hamzeh
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Heinz G Körschen
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Johannes M F G Aerts
- the Leiden Institute of Chemistry, Leiden University, 2333 CD Leiden, The Netherlands
| | - Wolfgang Bönigk
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Heike Endepols
- the Institute of Radiochemistry and Experimental Molecular Imaging (IREMB) and Department of Nuclear Medicine, University Hospital of Cologne, 50937 Cologne, Germany
| | - Roger Sandhoff
- the Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany.,the Lipid Pathobiochemistry Group, German Cancer Research Center, 69120 Heidelberg, Germany, and
| | - Matthias Geyer
- the Institute of Structural Biology, University Hospital, University of Bonn, 53127 Bonn, Germany
| | - Thomas K Berger
- the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| | - Frank Bradke
- the German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany
| | - Dagmar Wachten
- From the Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany, .,the Center of Advanced European Studies and Research (Caesar), 53175 Bonn, Germany
| |
Collapse
|
3
|
Abstract
The non-lysosomal glucosylceramidase GBA2 catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Loss of GBA2 function results in accumulation of glucosylceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP) and autosomal-recessive cerebellar ataxia (ARCA). Patients suffering from these disorders exhibit impaired locomotion and neurological abnormalities. GBA2 mutations found in these patients have been proposed to impair GBA2 function. However, the molecular mechanism underlying the occurrence of mutations in the GBA2 gene and the development of locomotor dysfunction is not well-understood. In this review, we aim to summarize recent findings regarding mutations in the GBA2 gene and their impact on GBA2 function in health and disease.
Collapse
Affiliation(s)
- Marina A Woeste
- Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany
| | - Dagmar Wachten
- Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany.,Molecular Physiology, Center of Advanced European Studies and Research, Minerva Max Planck Research Group, Bonn, Germany
| |
Collapse
|